60 Degrees Pharmaceuticals (SXTP) EBITDA Margin (2022 - 2026)
60 Degrees Pharmaceuticals (SXTP) posted quarterly EBITDA Margin of 1292.45% for Q1 2026, down 12405.0% year-over-year from N/an in Q1 2025, and down 104.51% quarter-over-quarter from 631.99% in Q4 2025.
60 Degrees Pharmaceuticals (SXTP) EBITDA Margin (2022 - 2026) Analysis & Trends
60 Degrees Pharmaceuticals (SXTP) has reported EBITDA Margin for 5 consecutive years, with 1292.45% the latest figure, recorded in Q1 2026.
- In Q1 2026, EBITDA Margin fell 12405.0% year-over-year to 1292.45%; the TTM figure through Mar 2026 stood at 791.09% (up 75427.0% YoY), while the FY2025 annual figure was 771.64%, up 82738.0% from the prior year.
- EBITDA Margin eased to 1292.45% in Q1 2026 per SXTP's latest filing, from 631.99% in the prior quarter.
- Across five years, EBITDA Margin topped out at 127.9% in Q3 2022 and bottomed at 5536.13% in Q1 2023.
- Historically, EBITDA Margin has averaged 1461.61% across 5 years, with a median of 1168.4% in 2025.
- On a YoY basis, EBITDA Margin climbed as much as 426576 bps in 2024 and fell as far as 315462 bps in 2024.
- 60 Degrees Pharmaceuticals' EBITDA Margin stood at 127.9% in 2022, then plunged by 445 bps to 696.81% in 2023, then decreased by 23 bps to 854.72% in 2024, then gained by 26 bps to 631.99% in 2025, then slumped by 105 bps to 1292.45% in 2026.
- Business Quant data shows SXTP's EBITDA Margin at 1292.45% in Q1 2026, 631.99% in Q4 2025, and 531.42% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 37.40% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 30.15% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 32.54% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -562.07% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 19.06% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 17.93% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -35.57% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.36% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 19.75% |
| 10 | 60 Degrees Pharmaceuticals | 3.00 Mn | 1.98 Mn | 56,798.00 | -1,092.41% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1,292.45% |
| Dec 31, 2025 | -631.99% |
| Sep 30, 2025 | -531.42% |
| Jun 30, 2025 | -1,590.01% |
| Mar 31, 2025 | -1,168.40% |
| Dec 31, 2024 | -854.72% |
| Sep 30, 2024 | -1,566.00% |
| Jun 30, 2024 | -3,351.75% |
| Mar 31, 2024 | -1,270.37% |
| Dec 31, 2023 | -696.81% |
| Sep 30, 2023 | -2,972.89% |
| Jun 30, 2023 | -197.13% |
| Mar 31, 2023 | -5,536.13% |
| Sep 30, 2022 | -127.90% |
| Jun 30, 2022 | -136.13% |